Nwamaka Nneka Onyedum

Nwamaka Nneka Onyedum

Auto-generated profile, based on publicly available information

Nwamaka Nneka Onyedum

Department of Haematology, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2026 in Australian Journal of Biomedical Research
Verified
Journal Article
Open access
PDF file
CGChidinma Lorretta Gab-Obinna
Chidinma Lorretta Gab-Obinna
IOIkemefula Oriaku
Ikemefula Oriaku
OOObiageri Ihuarulam Okeoma
Obiageri Ihuarulam Okeoma
AOAdepeju Kafayat Olowookere
Adepeju Kafayat Olowookere
EOEnobong Edoabasi Obong
Enobong Edoabasi Obong
JBJazuli Isyaku Bala
Jazuli Isyaku Bala
Background: Sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) remain major global health burdens. Ex vivo gene-editing therapies aim to achieve durable fetal hemoglobin (HbF) induction or direct mutation correction. Methods: We systematically reviewed clinical studies of CRISPR-Cas9 or base-editing therapies for SCD and TDT (MEDLINE, EMBASE, Web of Science, ClinicalTrials.gov, conference proceedings; 2010–03 December 2025). Eleven studies (>170 treated patients) reporting post-infusion outcomes were included. Results: All therapies produced robust, pancellular HbF (30–65%) and total hemoglobin in/near the normal range. In TDT (n > 100 evaluable), transfusion independence (≥12 months, Hb ≥9 g/dL) was achieved in 89–100% across platforms, sustained up to >4 years. In SCD (n > 60 evaluable), adjudicated vaso-occlusive crises were eliminated for ≥12 months in ≥97% of patients treated with exagamglogene autotemcel and 100% in smaller cohorts (EDIT-301, BEAM-101). No graft failures occurred. Serious adverse events and one death were attributable to busulfan conditioning, not editing. No therapy-related malignancies or confirmed harmful off-target edits have been reported, although follow-up remains limited (median ~18 months, longest >4 years). Conclusion: Current evidence from phase 1–3 trials demonstrates that ex vivo gene editing can achieve functional cure for many patients with TDT and severe SCD. Conditioning-related toxicity, limited long-term safety data, and delivery complexity remain critical barriers to broader implementation.

4 June 2025 in Journal of Cancer and Tumor International
Verified
Journal Article
Closed access
JSJosiah Stephen
Josiah Stephen
IKIkechukwu Kanu
Ikechukwu Kanu
NONwamaka Nneka Onyedum
Nwamaka Nneka Onyedum
EOEnibokun Theresa Orobator
Enibokun Theresa Orobator
CRCatherine Rono
Catherine Rono
LALawrence John Ajutor
Lawrence John Ajutor
HLA class I molecules are essential for presenting tumour antigens to cytotoxic T-cells, but their dysregulation in cancer enables immune evasion and limiting the efficacy of immunotherapies for cancer. The objective of this review is to explore the function of HLA class I changes in cancer development and their consequences for immunotherapy evolution. Examining peer-reviewed studies from 2010–2025 in PubMed and Scopus, a thorough literature review was done with a focus toward HLA class I expression, genetic defects, and immunotherapy outcomes in cancers including melanoma and lung cancer. HLA Class I Downregulation is a hallmark of tumour cells. Findings show that epigenetic silencing, β2-microglobulin mutations, or altered antigen-processing machinery are identified as the major mechanisms of HLA downregulation observed in 50–70% of tumours. These alterations are primary to therapeutic implications like poor responses to drugs like checkpoint inhibitors and they cause decreased T-cell infiltration. Research shows that in preclinical models, restoring HLA class I expression through cytokines, epigenetic modulators, or gene therapy are effective strategies in T-cell recognition and tumour clearance. Combining such approaches with PD-1/PD-L1 inhibitors produces synergistic effects that raise response rates by 20–40%. Furthermore, HLA class I status assessment can serve as an emerging possible biomarker for immunotherapy success. However, tumour heterogeneity and immunosuppressive microenvironments remain a challenge. Crucially, clinical studies to validate HLA class I restoration strategies and biomarker-driven patient stratification are underway to Investigate interactions between natural killer cell responses and HLA class I to help improve therapeutic approaches. Targeting therapies to reverse HLA class I defects through oncolytic viruses, along with integrating these with tailored immunotherapies are suggested future directions in immunotherapy.

10 December 2025 in Oncology, Nuclear Medicine and Transplantology
Verified
Journal Article
Closed access
CGChidinma Lorretta Gab-Obinna
Chidinma Lorretta Gab-Obinna
IOIkemefula Oriaku
Ikemefula Oriaku
OOOluchi Okechukwu
Oluchi Okechukwu
AOAdepeju Kafayat Olowookere
Adepeju Kafayat Olowookere
NONwamaka Nneka Onyedum
Nwamaka Nneka Onyedum
KTKwesi Egyin Taylor
Kwesi Egyin Taylor
Minimal residual disease (MRD) has become a significant predictor of relapse and survival in acute myeloid leukemia (AML), indicating the extent of remission beyond traditional morphological evaluation. Although multicolor flow cytometry and quantitative PCR are essential methodologies in minimal residual disease identification, both are constrained by immunophenotypic variability, the necessity for stable molecular targets, and limited sensitivity. Advancements in next-generation sequencing (NGS) have revolutionized the minimal residual disease (MRD) field by enabling highly sensitive, mutation-driven identification of leukemic clones across a broad genomic landscape. Contemporary error-suppressed next-generation sequencing techniques—such as unique molecular identifiers, duplex sequencing, and single-molecule molecular inversion probes—have enhanced analytical sensitivity to the 10⁻⁵ to 10⁻⁶ range, enabling the detection of ultra-low-frequency variations with greater specificity. These techniques improve clinical risk classification, refine prognostication within genetically defined AML subtypes, and guide therapeutic options, including post-remission therapy, targeted inhibition, and the timing and intensity of allogeneic stem cell transplantation. Innovative applications, such as single-cell sequencing, cell-free DNA studies, and integrative multi-omic MRD evaluation, enhance the capabilities of genomics-based monitoring. Nonetheless, obstacles remain, such as differentiating cancer mutations from clonal hematopoiesis, standardizing analytical pipelines, establishing clinically relevant thresholds, and incorporating NGS MRD into standardized treatment protocols. This review encapsulates contemporary NGS methods for AML MRD diagnosis, assesses their clinical ramifications and constraints, and suggests future pathways necessary for comprehensive clinical integration. With advancements in the area, NGS-based MRD is set to become a pivotal element of precision-guided AML control.